CARIBOU BIOSCIENCES Business Summary

Caribou Biosciences is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic licensing and collaboration agreements, most notably with Pfizer, alongside milestone payments and research grants. The firm operates as a single reportable segment focused on the development of "off-the-shelf" allogeneic CAR-T and CAR-NK cell therapies for hematologic malignancies and solid tumors. Its proprietary CRISPR hybrid RNA-DNA (chRDNA) platform distinguishes its pipeline—including lead candidates CB-010 (vispa-cel) and CB-011—by utilizing site-specific insertions and multi-gene edits to enhance antitumor activity and reduce off-target effects compared to first-generation CRISPR tools. Caribou competes directly with CRISPR Therapeutics, Intellia Therapeutics, Beam Therapeutics, and Allogene Therapeutics, positioning itself as a specialist in next-generation allogeneic persistence and genomic integrity within the genomic medicine landscape. The company was co-founded by Nobel Laureate Dr. Jennifer Doudna, a pioneer of CRISPR-Cas9 technology, and President and CEO Dr. Rachel Haurwitz, who has led the company since its 2011 inception. The executive leadership team includes Chief Financial Officer Sri Ryali, formerly of Codexis and Aimmune Therapeutics, and Chief Medical Officer Dr. Tina Albertson, who brings deep clinical development expertise from Lyell Immunopharma and Seagen. Caribou’s scientific pedigree is further bolstered by a board of directors featuring industry veterans from Amgen and Genentech, and the company maintains strong institutional backing from investors such as Pfizer, Fidelity, and Farallon Capital. As of early 2026, this leadership team is focused on advancing pivotal-stage trials for its oncology programs while managing a cash runway extended through the second half of 2027.